Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Effect of Mepolizumab in Severe Bilateral Nasal Polyps

ClinicalTrials.gov ID: NCT03085797

Public ClinicalTrials.gov record NCT03085797. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-blind, Parallel Group PhIII Study to Assess the Clinical Efficacy and Safety of 100 mg SC Mepolizumab as an Add on to Maintenance Treatment in Adults With Severe Bilateral Nasal Polyps - SYNAPSE (StudY in NAsal Polyps Patients to Assess the Safety and Efficacy of Mepolizumab)

Study identification

NCT ID
NCT03085797
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
414 participants

Conditions and interventions

Conditions

Interventions

  • Mepolizumab Drug
  • Placebo Drug
  • Mometasone furoate Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 24, 2017
Primary completion
Dec 10, 2019
Completion
Dec 10, 2019
Last update posted
Aug 2, 2021

2017 – 2019

United States locations

U.S. sites
34
U.S. states
21
U.S. cities
34
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35209
GSK Investigational Site Riverside California 92506
GSK Investigational Site Roseville California 95661
GSK Investigational Site San Diego California 92103
GSK Investigational Site Colorado Springs Colorado 80907
GSK Investigational Site Lake Mary Florida 32746
GSK Investigational Site Boise Idaho 83706
GSK Investigational Site Chicago Illinois 60657
GSK Investigational Site Des Moines Iowa 50312
GSK Investigational Site West Des Moines Iowa 50265
GSK Investigational Site Louisville Kentucky 40205
GSK Investigational Site Marrero Louisiana 70072
GSK Investigational Site White Marsh Maryland 21162
GSK Investigational Site Columbia Missouri 65201
GSK Investigational Site St Louis Missouri 63141
GSK Investigational Site Piscataway New Jersey 08854
GSK Investigational Site New York New York 10016
GSK Investigational Site Matthews North Carolina 28105
GSK Investigational Site Raleigh North Carolina 27607
GSK Investigational Site Winston-Salem North Carolina 27103
GSK Investigational Site Oklahoma City Oklahoma 73120
GSK Investigational Site Medford Oregon 97504
GSK Investigational Site Bethlehem Pennsylvania 18017
GSK Investigational Site Pittsburgh Pennsylvania 15213
GSK Investigational Site Charleston South Carolina 29425
GSK Investigational Site Orangeburg South Carolina 29118
GSK Investigational Site Dallas Texas 75235
GSK Investigational Site McKinney Texas 75070
GSK Investigational Site San Antonio Texas 78258
GSK Investigational Site North Logan Utah 84341
GSK Investigational Site Salt Lake City Utah 84102
GSK Investigational Site Lynchburg Virginia 24501
GSK Investigational Site Norfolk Virginia 23507
GSK Investigational Site Richmond Virginia 23235

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 67 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03085797, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 2, 2021 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03085797 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →